Talkspace, Inc.
NASDAQ:TALKMedical - Care Facilities
+$0.01 today
- Market cap
- $879.44M
- Beta
- 1.07
- P/E (TTM)
- 749.9
- EPS (TTM)
- $0.01
Volume 2.41M
Average 2.55M
TALK Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Talkspace, Inc.NASDAQ: TALK
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.96M rose 26.8% year over year, ahead of the -157.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 54.4% from the prior quarter. Over 3 fiscal years it compounded at -11.3% a year.
Context
- Stock-based compensation amounted to 3.7% of revenue in FY2025, down 1.2 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +26.8% holds above the trailing-twelve-month pace of -157.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 8.45M USD
- Year-over-year change
- -7.9%
- 4-year CAGR
- -25.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.45M | -7.9% |
| FY2024 | 2024-12-31 | 9.17M | +9.3% |
| FY2023 | 2023-12-31 | 8.4M | -30.7% |
| FY2022 | 2022-12-31 | 12.12M | -55.8% |
| FY2021 | 2021-12-31 | 27.41M | — |
Stock-Based Compensation vs competitors
How TALK compares with its peers on the latest reported figures
- TALK's LTM Mar 2026 stock-based compensation of $5.31M is the 8th largest of the 11 companies compared; the peer median is $6.54M.
- Its year-over-year change of -157.3% is the lowest of 8, against a peer median of -10.7%.
- Stock-based compensation amounts to 2.2% of revenue for TALK, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.84M | +21.4% | +0.9% | 4.3% | |
| LTM Mar 2026 | $12.55M | -31.5% | +1.2% | — | |
| LTM Mar 2026 | $12.5M | -10.7% | -7.5% | 1.7% | |
| LTM Mar 2026 | $8.49M | +16.1% | +25.6% | 20.9% | |
| LTM Mar 2026 | $6.61M | -43.9% | -57.1% | 4.4% | |
| LTM Mar 2026 | $6.47M | +35.8% | +5.3% | 1.6% | |
| LTM Dec 2025 | $5.38M | — | — | 4.6% | |
| LTM Mar 2026 | $5.31M | -157.3% | -11.3% | 2.2% | |
| LTM Mar 2026 | $3.36M | -56.6% | +26.8% | 0.4% | |
| LTM Mar 2026 | $3M | — | — | 0.0% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $0 | — | — | 0.0% |
| Peer median (excluding TALK) | $6.54M | -10.7% | +1.2% | 1.7% | |
Competitors are the stored peer set for TALK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (62.74M) | (79.67M) | (19.18M) | 1.15M | (5.22M) |
| Depreciation & Amortization | 1.97M | 1.36M | 1.2M | 859K | 2.88M |
| Deferred Income Tax | (31.78M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 27.41M | 12.12M | 8.4M | 9.17M | 8.45M |
| Change in Working Capital | (738K) | 2.12M | (7.55M) | 895K | (8.23M) |
| Accounts Receivables | 402K | (4.13M) | (534K) | 531K | (6.42M) |
| Inventory | (3.66M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 503K | (968K) | (350K) | 1.6M | 791K |
| Other Working Capital | 2.01M | 7.21M | (6.67M) | (1.24M) | (2.6M) |
| Other Non-Cash Items | 175K | 3M | 748K | (371K) | 10.66M |
| Operating Cash Flow | (65.71M) | (61.08M) | (16.39M) | 11.7M | 8.53M |
| Capital Expenditures | (663K) | (350K) | (151K) | (5.44M) | (10.64M) |
| Acquisitions (Net) | 0 | 33K | 10K | 0 | (4.9M) |
| Purchases of Investments | 0 | 0 | 0 | (41.12M) | (49.34M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 36.08M |
| Other Investing Activities | 0 | 0 | 0 | (171K) | (10.71M) |
| Investing Cash Flow | (663K) | (317K) | (141K) | (46.73M) | (28.88M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 251.43M | 3.18M | 2.71M | 2.01M | 913K |
| Common Stock Repurchased | 0 | 0 | 0 | (11M) | (17.2M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50K) | (1.5M) | (810K) | (1.19M) | (2.71M) |
| Financing Cash Flow | 251.38M | 1.68M | 1.9M | (12.19M) | (19M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 185.01M | (59.71M) | (14.64M) | (47.22M) | (39.34M) |
| Free Cash Flow | (66.37M) | (61.43M) | (16.54M) | 6.26M | (2.11M) |
Talkspace, Inc.
NASDAQ:TALK
Intrinsic Alpha fair value
Locked
Current Price
$5.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.